Epstein Files Search

Dataset

Sort

Status

DOJ Status

Date Range

–

Page Count

–

Corpus: 1990-03-17 – 2025-12-01

December 2025

Mo

Tu

We

Th

Fr

Sa

Su

None

Light

Medium

Heavy

Results by Dataset1 total

Set 9

1

1 result for “"HLA A2 NSCLC"”

EFTA01113739Set 9

37p2,922w

NSCLC pts) OSE EFTA01113747 OSE 2101:Phase Ill Protocol & Objectives HLA A2 NSCLC population, open, randomized, multi-center comparative study: 500pts ■ Versus reference drug (Treatment of Physician's Choice) after ... targeted cancer immune therapy with positive phase II: Phase III in advanced HLA A2+ NSCLC pts: global costs: €23M (including team and G&A) 12/18 months Milestones: Total 4M€ • Orphan ... 12/18 months: 0SE 2101 targeted cancer immune therapy phase III in advanced HLA A2+

Keyboard Shortcuts

/

Focus search

Esc

Blur input

O

Open PDF

←→

Paginate

NSCLC

0SE 1101 H4R agonist Phase II in CF pts — Orphan status for both opportunities — FDA/EMEA

https://www.justice.gov/epstein/files/DataSet%209/EFTA01113739.pdf